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PRECLINICAL DEVELOPMENT OF EPICERTIN, A NOVEL BIOTHERAPEUTIC 
FOR THE TREATMENT OF ULCERATIVE COLITIS 
Micaela Ann Reeves 
April 6, 2021 
Epicertin (EPT) is a recombinant variant of the cholera toxin B subunit with a C-
terminal KDEL endoplasmic retention motif. Previously, orally administered EPT 
demonstrated mucosal healing activity in acute and chronic dextran sulfate sodium colitis 
models, indicating its therapeutic potential for ulcerative colitis (UC) treatment. 
However, oral dosing with EPT requires neutralization of gastric acid prior to 
administration, hindering its facile application in the treatment of chronic diseases like 
UC. One solution to this issue is that EPT may also be administered intracolonically 
without losing efficacy. This work describes the determination of a target intracolonic 
dose of EPT for future first-in-human safety trials as well as the development of a 
prototype oral formulation of EPT that prevents stomach acid degradation for pH-
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CHAPTER 1: INTRODUCTION 
 
 The cholera toxin B subunit (CTB) is the homopentameric subunit of the cholera 
toxin. The cholera toxin is comprised of this nontoxic B subunit and the toxic catalytic A 
subunit [1-3]. CTB binds to GM1 ganglioside to mediate entry of the whole toxin into the 
cell via retrograde transport to the endoplasmic reticulum (ER) [4]. CTB exhibits strong 
immunomodulatory effects under normal and various immunopathological conditions [5, 
6]. For example, a WHO pre-qualified oral cholera vaccine, Dukoral®, contains heat-
killed whole cell Vibrio cholerae and recombinant CTB [5, 7]. However, CTB can induce 
potent mucosal and systemic antibody responses in humans on its own [8-10]. A plant-
made recombinant CTB variant, epicertin (EPT), featuring a C-terminal hexapeptide ER 
retention motif -KDEL exhibits mucosal healing activity unlike CTB. A unique feature of 
EPT is its established ability to be efficiently manufactured in a Nicotiana benthamiana 
transient production system [11]. EPT was initially engineered as a potential solution to 
the cost and scale challenges in CTB biomanufacturing to aid in mass vaccination against 
cholera outbreaks [12, 13]. However, EPT may have a separate role as a potential novel 
therapeutic for ulcerative colitis [14].  
Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD), 
characterized by chronic and relapsing inflammation of the innermost layer of the colon 
and rectal mucosa [15, 16]. Its etiology remains poorly understood and the onset is 
associated with a complicated interplay of genetic and environmental factors as well as gut 
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microbiota [17]. The disease often manifests as a multitude of symptoms: bloody diarrhea, 
rectal bleeding, fatigue, and weight loss. However, symptom presentation often varies 
among patients and may change over time with increasing severity of disease [16]. The 
Crohn’s and Colitis Foundation estimates that approximately 1.6 million Americans suffer 
from IBD with a total US annual financial burden between $14.6 billion and $31.6 billion. 
UC accounts for 907,000 of these cases with an annual incidence of 12.2 per 100,000 
people [16]. Current FDA-approved UC drugs aim to treat existing symptoms, maintain 
remission, and improve quality of life. Despite multiple treatment options available to UC 
patients, none of them can cure the disease, and up to a third of those with 30+ years of the 
disease will require surgical removal of the colon and rectum [16]. 
 There are several classes of drugs used to treat UC [16]. Typically, UC treatment 
follows a step-up approach in which drug class utilization is dependent upon disease 
severity and response to prior therapies. The final step of this treatment strategy is 
surgical intervention [18, 19]. Treatment with 5-aminosalicylates (ASAs) has long been 
the mainstay first-line therapy for mild-to-moderate UC [16, 20]. This inflammation-
blunting class of therapeutics are preferred for early-stage UC because of their generally 
innocuous side effect profiles, although moderate UC is often unresponsive to these 
agents [19]. The mild side effect profile is counteracted by the ability of patients to 
develop tolerance during remission maintenance and require new treatment strategies. 
Failure to achieve or maintain remission with 5-ASAs is typically followed by treatment 
with corticosteroids and steroid-sparing immunomodulators. An estimated two-thirds of 
patients receiving short-term steroid treatment for moderate to severe UC achieve 
remission. However, the risk of serious adverse effects limit long-term use of these 
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agents [18-21]. Biologics (e.g. anti-TNFα and anti-integrin monoclonal antibodies) have 
traditionally been the final agents utilized to treat severe UC prior to surgical resection of 
the colon and rectum, although recent literature suggests the benefit of using biologics in 
earlier stages [22]. These drugs are effective in remission induction and maintenance in 
patients following previous treatment failures but are partnered with the serious side 
effects including severe infection and increased cancer risk [20, 21]. Of particular note, 
fewer than half of patients treated with biologics are able to achieve mucosal healing, an 
endoscopic marker found to be highly predictive of sustained clinical remission, better 
quality of life, and decreased risk for colitis-associated colorectal cancer [23, 24]. 
Further, biologics are typically more expensive than other therapeutic agents [25]. 
Therefore, there is a current unmet need in UC therapy: agents that can directly restore 
the damaged epithelial barrier and facilitate mucosal healing without suppressing immune 
function such as EPT. In this chapter, I will summarize previous studies describing the 
mucosal healing activity of EPT, discuss the current EPT formulations under 
investigation and limitations as well as describe other potential formulation options. 
 
1.1. EPT facilitates mucosal healing: A novel therapeutic target for ulcerative colitis. 
  
 Although originally designed to aid mass vaccination efforts against cholera 
outbreaks, we also assessed the immunomodulatory effects of EPT. Two weeks after two 
oral 30 µg administrations of EPT, immune cell population analysis from the small 
intestine, colon, Peyer’s patches, and spleen revealed that subsets of innate immune cell 
populations in the lamina propria of the colon were significantly increased in EPT-treated 
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mice compared to control (M1 and M2 macrophages confirmed by 
immunohistochemistry, natural killer [NK] cells). T helper (Th)2, regulatory T (Treg) and 
Th17 cells were also increased following administration of EPT. Gene expression 
analysis further supported that EPT has a more targeted impact on the colon as 871 genes 
were significantly altered in the colon (p < 0.01) while 184 genes were significantly 
altered in the small intestine in mice treated with EPT compared to vehicle control. Oral 
administration of EPT was shown to induce TgfbI, TgfbII receptor and Smad regulation, 
all of which are genes involved in transforming growth factor (TGF)β-associated 
pathways and epithelial wound healing [26]. For this reason, epithelial restitution 
potential of EPT was assessed using a human colon epithelial cell (Caco2) scratch assay. 
EPT significantly enhanced epithelial cell migration similarly to the TGFβ1 control 
compared to the vehicle control phosphate buffered saline (PBS) at 24 and 48 h post 
scraping the cell layer. Cell culture supernatant analyzed at 48 h showed that epicertin 
and TGFβ1 had similar inflammation and wound healing-related profiles relative to 
cytokines like epidermal growth factor (EGF), granulocyte colony-stimulating factor (G-
CSF), granulocyte-macrophage (GM)-CSF, interferon (IFN)-γ, interleukin (IL)-10, IL-6, 
and tumor necrosis factor (TNF)α. This effect translated to an in vivo model of acute 
colitis induced by dextran sulfate sodium (DSS). EPT treatment significantly blunted 
weight loss induced by DSS and hematoxylin and eosin (H&E)-stained distal colon tissue 
at 6 days post-DSS exposure reveled that EPT administration prevented crypt loss and 
ulceration compared to vehicle control. However, the numbers of infiltrating 
macrophages into the colon mucosa were similar between EPT and vehicle groups. 
Another in vivo study was performed to assess the immediate impact of EPT treatment on 
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acute DSS-induced colitis. Mice were orally administered 30 µg EPT or PBS twice 
before DSS exposure. A reference group of mice dosed daily with 100 µg mesalazine 
during DSS exposure was also included. EPT- and mesalazine-treated mice similarly 
reduced mucosal damage as characterized by shorted yet visible basal crypts, mild 
inflammatory infiltrates, and epithelial cell surface retention. Gene expression and 
cytokine analysis from the distal colon showed that EPT treatment blunted escalation of 
inflammatory markers including IL-1β, IL-6, and IFN-γ among others. In an 
azoxymethane (AOM)/DSS mouse model of chronic colitis and colon cancer, biweekly 
EPT administration (3 µg) significantly decreased disease activity index (DAI) scores 
following the first dose and more dramatically during the third DSS exposure period. 
This is a standard scoring system assessing the overall severity of colitis, which takes an 
average of scores from three categories: body weight, stool consistency, and blood in 
stool [27]. Tumorigenesis was also significantly reduced in both dose groups treated with 
EPT [14]. Taken together, these results highlight the potential role of EPT in UC therapy 
as a mucosal healing agent that specifically targets the colon. 
 
 Mucosal healing is a major treatment goal for UC patients [23, 24, 28, 29]. It is a 
complex and dynamic process involving multiple cell types including epithelial, stromal, 
and immune cells [28]. Epithelial repair plays a crucial role in mucosal healing by 
rebuilding the intestinal barrier to inhibit inflammation caused by entry of bacteria into 
the mucosa. Since inflammation in UC is limited to the innermost layer of the colon and 
rectal mucosa, epithelial repair may be key to effectively achieving mucosal healing in 
this subset of IBD patients [16, 23]. Currently there is no UC drug approved by FDA that 
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specifically aims at recovering the colon epithelial barrier integrity. Thus, an epithelial 
repair agent, such as EPT, may fill a current treatment gap for UC. 
 
We continued to investigate the mechanism of EPT-induced mucosal healing via 
epithelial repair, specifically the importance of its ER retention motif [30]. To test the ER 
retention activity of EPT, Caco2 cells were treated with EPT or CTB for 24 h and cell 
lysates were monitored for CTB retention for 24 h. While CTB showed decreasing levels 
of retention with only marginal amounts detected at 24 h, EPT was continuously detected 
in cell lysates over 24 h. These results were corroborated with confocal microscopy in 
which EPT was depicted at much higher amounts inside Caco2 cells at 6 and 24 h 
compared to CTB. Coimmunoprecipitation results also indicated that EPT displayed clear 
binding to KDEL receptors that was not observed with CTB. These data indicate that 
EPT has prolonged residence in Caco2 cells due to its KDEL receptor interaction.  
 
In Caco2 cells treated with EPT, CTB, a non-GM1 binding mutant of EPT (G33D 
EPT) or PBS, it was demonstrated that all 3 sensors of the unfolded protein response 
(UPR) pathways were upregulated at gene expression and protein levels only in EPT-
treated cells [30]. The UPR is a system in which the ER can activate various intracellular 
signaling pathways to alleviate the accumulation of aberrant proteins. However, this 
response can also be triggered by adventitious proteins invading the ER, such as CTB 
[31, 32]. One branch of the UPR, the inositol-requiring enzyme 1 (IRE1)- X-box binding 
protein 1 (XBP1) pathway has been linked to wound healing and mitigation of DSS 
colitis [33-35]. Some of the markers of the UPR analyzed were activating transcription 
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factor 6 (ATF6), PKR-like ER kinase (PERK), IRE1, and immunoglobulin heavy chain-
binding protein (BiP). Consistent with the Caco2 study, mouse primary colon epithelial 
cells treated with EPT for 24 h also significantly increased levels of IRE1α, PERK, and 
BiP compared to CTB and PBS-treated groups. A further coimmunoprecipitation assay 
indicated that Caco2 cells incubated with CTB or EPT for 1 h both were shown to 
interact with the ER chaperone, BiP, however, only EPT was shown to interact with BiP 
after 24 h. To test the impact of the UPR on EPT’s wound healing activity, a Caco2 
scratch assay was performed in which cells were treated with EPT in the presence or 
absence of 4µ8C, a chemical inhibitor of the IRE1-XBP1 arm of the UPR. The UPR 
inhibitor was sufficient to completely block the wound closure activity of EPT, indicating 
that EPT exhibits wound healing activity via the IRE1-XBP1 signaling pathway [30].  
 
Since EPT was demonstrated to activate an UPR in primary mouse colon 
epithelial cells, it was hypothesized that this enhanced epithelial repair was mediated by 
the IRE1 arm of the UPR. Most interestingly, these findings were also evaluated in 
human colon tissues ex vivo [30]. A sigmoid colon tissue of a UC patient who underwent 
total colectomy was sectioned into 9 pieces and cultures with EPT, CTB, or PBS (n=3) 
for 24 h. Following incubation, UPR, TGF-β, and wound healing gene expression was 
analyzed. Consistent with Caco2 cell results, EPT-treated tissue showed a significant 
upregulation in the IRE1 gene (ERN1), PERK gene (EIF2AK3), and TGF-B1 with no 
significant difference observed between PBS- and CTB-treated tissues. Histopathological 
analysis showed the EPT-treated tissues also had early-stage crypt formations with low 
mucosal neutrophil infiltration, both of which were not seen in the PBS- or CTB-treated 
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tissues. Altogether, the results of this study indicate that EPT has unique colon mucosal 
wound healing effects related to its ER retention and subsequent activation of the UPR 
[30]. 
 
In another study we evaluated the efficacy of EPT in the treatment of chronic 
colitis as well as addressed consequences of immunogenicity [36]. A chronic DSS colitis 
experiment in which mice were exposed to three cycles of 7-day DSS in drinking water 
followed by 14-day normal drinking water was performed (total in-life study period of 63 
days). Mice were treated orally with 3 µg EPT or PBS once weekly starting on day 7, 
with 3 µg EPT or PBS once weekly starting on day 35, or with 3 µg EPT or PBS every 3 
days starting at day 35 (6 dosing groups total). All EPT-treated groups showed immediate 
reduction in DAI scores. Mice receiving weekly EPT treatment starting from day 7 and 
every-3-day treatment from day 35 appeared to have improved barrier function compared 
to PBS-treated groups as indicated by serum FITC-dextran measurements at the 
conclusion of the study on day 63. No EPT treatment groups demonstrated an elevation 
of analyzed pro-inflammatory cytokines (IL-1β, TNFα, GM-CSF, and IFN-γ). Once 
weekly treatment with EPT starting at day 7 significantly decreased GM-CSF and IL-1β 
levels compared to PBS, and once weekly treatment with EPT starting at day 35 
significantly decreased GM-CSF and IFNγ levels compared to PBS. Histopathological 
examination corroborated the DAI, FITC-dextran, and cytokine analyses. Mice dosed 
with EPT once weekly starting from day 7 or every-3-day starting from day 35 
demonstrated similar recovery and exhibited less crypt branching, crypt distortion, and 
expansion of the lamina propria than weekly dosing starting at day 35. These results 
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taken together indicate that once weekly or every-3-day EPT dosing can effectively 
mitigate chronic colitis and that the efficacy is maintained over a long period, raising an 
interesting question about the consequences of an immune response to the protein, which 
is derived from the mucosal immunostimulatory protein CTB. 
 
To probe the potential impacts of anti-drug antibodies, an acute DSS study was 
performed in which three groups of C57Bl/6 mice were administered either two oral 
doses of 30 µg EPT prior to DSS exposure, dosed only one therapeutic dose of 3 µg EPT 
on the final day of 7-day DSS exposure, or received both two oral doses of 30 µg EPT 
prior to DSS exposure and one therapeutic dose of 3 µg EPT on the final day of DSS 
exposure. Anti-EPT IgA titers were assessed on days 7 and 14 to determine if the 
immunogenicity of EPT impacts its efficacy. All EPT-treated groups showed a 
significantly more rapid body weight recovery after DSS cessation and all EPT groups 
showed similar DAI scores that were significantly lower than the PBS-treated mice. Both 
groups in which mice were dosed prior to DSS exposure had similar and high levels of 
anti-EPT IgA antibodies at days 7 and 14, indicating that anti-drug antibodies were 
present when EPT was administered therapeutically. Under the same experimental 
condition in C3H/HeJ mice, which are poor responders to CTB immunization, all EPT 
epicertin dose regimens were efficacious against DSS colitis compared to PBS-treated 
mice in terms of body weight recovery, colon length and DAI scores. Unlike the 
C57BL/6 mice, however, these mice had little or no anti-CTB IgA response to pre-dosing 
with EPT, indicating that EPT’s therapeutic effects are unlikely dependent on IgA 
induction in the intestine. These results demonstrate that the immunogenicity of EPT 
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dosing does not seem to impede its mucosal healing efficacy, further supporting the 
potential role of this molecule as a novel therapeutic for UC [36]. 
 
1.2. Current production process and formulation of EPT 
 
The EPT production process has continuously been optimized over the last several 
years [11-13, 37]. This variant of CTB is transiently overexpressed in a species of tobacco, 
Nicotiana benthamiana. Utilization of the GENEWARE® tobacco mosaic virus vector, we 
are able to purify approximately 400 mg of EPT per kg of leaf tissue [37]. EPT is expressed 
using the GENEWARE® tobacco mosaic virus vector and inoculated into 21-day old N. 
benthamiana. Eleven days post-infection leaf tissues are harvested and EPT is extracted 
using a commercial blender and a 1:2 ratio of leaf tissue to extraction buffer. Following 
filtration and centrifugation steps, the supernatant is heated at 50°C for 45 min and 
undergoes further centrifugation to precipitate starches and host proteins. The pH of the 
resulting supernatant is adjusted from pH 5.0 to 8.0 to precipitate the one more round of 
host proteins prior to purification. The EPT-containing supernatant is first purified by 
immobilized metal affinity chromatography (IMAC) using a metal affinity resin charged 
with CoCl2. This purification method utilizes CTB’s ability to bind to divalent metal 
cations through internal histidine residues [38]. A second chromatography step using a 
ceramic hydroxyapatite resin with a gradient phosphate buffer elution step is used to isolate 
fully intact EPT from EPT species with truncations of the C-terminal -KDEL motif. By 
this two-step chromatography method we are able to achieve approximately 95% purity of 
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fully intact EPT [11]. The resulting drug product is a solution of  EPT in PBS (pH 7.4) that 
is stored at 4°C. 
EPT may be administered to the colon topically or by oral gavage to alleviate DSS-
induced colitis in mice [30]. Although oral medications are generally preferred by patients 
and increase patient adherence to treatment regimens [17, 39, 40], oral administration of 
EPT solution requires neutralization of stomach acid to prevent degradation of the protein. 
This is similar to the WHO prequalified oral cholera vaccine, Dukoral®, which is 
administered in a solution following stomach neutralization with a sodium bicarbonate 
solution. Considering potential long-term treatment necessary for the management of UC 
[41], this neutralization step could be disadvantageous as it would likely lower patient 
adherence and ease of administration. Intracolonic administration is another option for 
EPT, as many UC drugs are enemas. However, enema formulations have their own 
advantages as well as limitations. 
 
1.3. Routes of administration with respect to ulcerative colitis. 
 
 Deciding on a route of administration for a drug is not necessarily an easy choice 
when presented with multiple formulation possibilities. For EPT, several factors must be 
taken into consideration when deciding whether to move forward with an enema or oral 
formulation. An enema formulation has the benefit of direct topical application to the 
target site as well as lower potential for systemic off-target effects [17]. This would 
decrease the number of safety concerns that would need to be addressed during 
preclinical and clinical investigations. Intracolonic administration allows for rapid 
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absorption of the drug and ensures delivery of optimal dosage as it by-passes first-pass 
metabolism [17]. Enema formulations can be especially beneficial to treat UC affecting 
the rectum and most distal sections of the colon [17]. However, enema formulations run 
the risk of decreasing patient adherence and are not as easily administered, two important 
factors to consider when developing drugs to treat chronic diseases like UC [41].  
 Oral medications are generally preferred by patients, which increases the 
likelihood that patients will adhere to treatment regimens [17, 39, 40]. They are easier for 
patients to self-administer and can be formulated with delivery systems to extend release, 
prevent stomach acid degradation, and allow for release of capsule contents at a specific 
pH [17, 40]. These benefits are countered with the need for higher doses to compensate 
for drug loss after first-pass metabolism and potential absorption throughout the GI tract 
prior to delivery at the target site [17]. Higher doses correspond to increased production 
costs per dose and ultimately higher costs for the patient. Further, development and 
production systems required to manufacture a drug with a specialized coating or delivery 
system can slow research efforts and become costly. With respect to EPT, an enema 
formulation is suitable for early safety and efficacy studies in humans, however, an 
improved solid oral formulation allowing for release at the distal colon would be optimal 
due to the need for adherence in the treatment of chronic diseases like UC. 
 
1.4. Oral drug delivery options and dried formulations. 
 
 Biotherapeutics are often limited in their use as orally administered agents in UC 
due to degradation in the gastrointestinal tract, large molecular size, and poor permeation 
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[42]. Therefore, the formulation of the drug product must be optimized to circumvent 
these issues. There are a variety of oral formulations currently used and more under 
investigation for the manufacturing of biotherapeutics. The formulation strategy 
employed depends on the properties of the drug itself. For example, poorly soluble drugs 
can be delivered by reducing particle size or adding surfactants to the drug substance 
[43]. Nanoparticle drug delivery systems are often used to protect a drug from the harsh 
environment of the gastrointestinal tract [44]. Another drug delivery system commonly 
used is an enteric polymer coating allowing for site-specific delivery based on pH. These 
coatings are designed to remain stable and intact through the gastrointestinal tract and 
degrade once exposed to a specific pH. This would be beneficial to prevent degradation 
of EPT in the gastric acid. Other coatings are microflora-triggered and are biodegraded 
by bacterial flora in the colon [43]. Drugs that utilize these coatings are often tablets or 
capsules filled with lyophilized or spray-dried drug substances. 
 
 There are two main dehydration processes in the world of pharmaceutical and 
biopharmaceutical development: spray drying and freeze drying (lyophilization) [45]. 
The primary drying method in industrial settings, lyophilization, is a two-step process in 
which ice is sublimated from frozen drug product followed by desorption of remaining 
water at low pressure and higher temperature to form a dried cake [46]. If a fine powder 
is required, another process must be added to break up the final cake [47]. The addition of 
this secondary step removes a certain amount of control from the manufacturers, reduces 
efficiency and increases production time [47, 48]. Spray drying technology was originally 
improved to aid formulation development of small molecule drugs but has gained 
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popularity in the world of biopharmaceuticals in recent decades. In contrast to 
lyophilization, spray drying is a one-step process in which the protein solution is 
atomized into a hot air-drying chamber and resulting particles settle in a product collector 
[48-50]. Although biopharmaceutical spray drying has its limitations on an industrial 
scale, it offers the following advantages to lyophilization: consistent powder quality, 
increased production control necessary to follow current Good Manufacturing Practice 
(cGMP) guidelines, significant energy cost savings, a wide range of dryer designs for 
specific applications, and ability to dry heat-sensitive and heat-resistant inputs [45]. For 
this reason, in addition to continuing to evaluate safety and efficacy of an intracolonic 
formulation of EPT, we began to develop an optimal oral formulation: a spray-dried 
capsule with an enteric polymer coating allowing for pH-dependent release at the colon. 
The results herein describe a dose analysis study to determine an optimal dose level for 
intracolonically delivered EPT, as well as a prototype production process for a spray-

















CHAPTER II: MATERIALS AND METHODS 
 
EPT production. EPT was produced in Nicotiana benthamiana using a transient 
overexpression system and purified to > 95% homogeneity with an endotoxin level of <3 
endotoxin units per mg as described previously [11, 12, 37]. EPT was 
ultrafiltrated/diafiltrated into various buffers (Table 1) using 30,000 MWCO centrifugal 
devices. PBS with 100 mM mannitol was found to be the optimal buffer for spray drying of 
EPT. EPT at 1 mg/mL in PBS with 100 mM mannitol excipient (pH 7.2) was dehydrated 
using a Büchi B-290 mini spray drier with an inlet temperature of 125°C and an outlet 
temperature maintained between 65 and 67°C. The Q-Flow was 35 mm, aspirator was 90% 
and pump 20%.  EPT powder was stored in conical tubes wrapped in parafilm under 
desiccation at room temperature (20-25ᵒC) until use. Standard EPT used for the GM1/KDEL 
ELISA and SEC-HPLC was produced in Nicotiana benthamiana using a transient 
overexpression system and purified to > 95% homogeneity with an endotoxin level of <3 
endotoxin units per mg as described previously [11, 12, 37] 
 
Acute DSS colitis model and EPT treatment for intracolonic dose level determination 
study. Groups of 10 female C57BL/6 mice, randomly assigned, were used. 3% DSS (M.W. 
36,000 – 50,000; M.P. Biomedicals, Santa Ana, CA) was administered in drinking water ad 
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libitum for 7 days.1 Body weights were monitored daily from the start of DSS exposure to 
sacrifice on day 12. On the last day of DSS exposure, animals were intracolonically 
administered 100 µL of  PBS, 0.01 µM EPT, 0.1 µM EPT, or 1 µM EPT (corresponding to 
0.0614 mg, 0.614 mg, or 6.14 mg EPT per animal). Animals recovered with normal drinking 
water for 5 days. Disease activity index (DAI) scores, consisting of body weight loss, fecal 
consistency and occult blood tests, were recorded following sacrifice and performed as 
previously described [51]. Distal colon tissues were fixed in neutral buffered formalin and 
stained with hematoxalin and eosin (H&E). Histopathological scores, a combination score 
comprised of crypt architecture, inflammatory infiltrate, muscle thickening and goblet cell 
presences scores, were determined as previously described [52, 53]. Each category was 
ranked on a scale from 0 to 3 and summed to obtain a single histopathological damage score 
for each tissue. 
 
EPT powder characterization. To measure residual moisture, a 5.9 mg portion of dried 
powder was incubated at 70oC for 16 h. Moisture content was calculated by weighing the 
difference before and after heating. To determine solubility, dried powder was weighed and 
a calculated volume of milli Q water was added to reconstitute EPT powder to 1 mg/ml. The 
concentration of the reconstituted solution was measured by Nanodrop (Thermo Fisher 
Scientific) using an extinction coefficient at A280 of 0.7857. The percent solubility was 
calculated based on the difference in 1 mg/mL vs the determined nanodrop concentration.  
 
 
1 Eight-week-old C57BL/6J, female mice were obtained from Jackson Laboratories (Bar 
Harbor, ME). The University of Louisville’s Institutional Animal Care and Use Committee 
approved all animal studies conducted in this thesis. 
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Percent monomer was determined by size-exclusion high performance liquid 
chromatography (SEC-HPLC). SEC-HPLC was run as previously described [17]. Briefly, 
reconstituted EPT at 1 mg/mL was applied to a Tosoh TSKgel SuperSW3000 column using 
100 mM sodium phosphate, pH 7.2, 150 mM sodium chloride running buffer. EPT standard 
(a bulk solution prepared in PBS before spray drying) was used as a control.  
 
GM1-capture KDEL-detection (GM1/KDEL)-ELISA. The assay was done as described 
in Morris et al. [11]. Plates were coated with 100 µL per well of 2 µg/mL GM1 ganglioside 
(Sigma Aldrich; St. Louis, MO) diluted in a coating solution consisting of 3 mM sodium 
azide, 15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6. After overnight 
incubation (16 to 18 h) at 4ᵒC, plates were washed three times with PBST (0.05% Tween 20 
in 1X PBS) and blocked with a blocking solution (5% non-fat dry milk, 0.05% Tween 20 in 
1X PBS) for 1 h at room temperature, then washed with PBST thrice. Three-fold serially 
diluted, duplicate samples (100 µL/well) were added to plates in 1% PBSTM (1% dry milk, 
0.05% Tween 20 in 1X PBS). Samples were incubated on plates for 1 h at 37ᵒC. Plates were 
washed and mouse anti-KDEL monoclonal antibody (Enzo Life Sciences; Farmingdale, NY) 
diluted 1:1,000 in 1% PBSTM (100 µL/well) was added; plates were then incubated at 37ᵒC 
for 1 h. Plates were washed and goat anti-mouse IgG-HRP (Southern Biotech; Birmingham, 
AL) diluted 1:5,000 in 1% PBSTM was added, followed by incubation at 37ᵒC for 1 h. Plates 
were washed a final time and developed with 3,3',5,5'-tetramethylbenzidine substrate (TMB). 
The reaction was stopped with 2 N sulfuric acid and the absorbance at 450 nm was 




EPT capsule package and preparation. Torpac size M gelatin capsules were packed with 
3 mg dried EPT product per capsule (corresponding to 5 µg of EPT) using the ProFunnel 
capsule filling system (Torpac; Fairfield, NJ). Capsule cap and body joints were painted with 
4% Eudragit L100 anionic polymer coating solution and allowed to dry for 20 min. Capsules 
were loaded into a size M capsule holder and dipped just past the cap and body joints into 
4% Eudragit L100 coating solution and allowed to dry for 25 min. Capsules were flipped and 
reloaded into the holder and dipped past the cap and body joints into 4% Eudragit L100 
coating solution. Dipping of capsules was repeated with 20% Eudragit L100 coating solution. 
 
Capsule disintegration test. Individual EPT-containing enteric-coated capsules (n=5) were 
submerged in 1 N hydrochloric acid for 2 h at room temperature. Acid submerging each 
Table 1.  
 
Determination of optimal buffer excipient for EPT powder production. 
Buffer % Monomer % Moisture % Solubility 
PBS 4.9 2.9 106 
PBS, 20 mM Mannitol 4.5 10.3 94 
PBS, 100 mM Mannitol 3.1 0 97 
PBS, 150 mM Mannitol 9.1 7.5 99 
PBS, 250 mM Mannitol 6.4 4.1 87 
30 mM Phosphate, pH 7 3.2 31.5 67 
30 mM Phosphate, 20 mM Mannitol, pH 7 1.1 14.7 81 
30 mM Phosphate, 100 mM Mannitol, pH 7 5.8 2.3 97 
30 mM Phosphate, 150 mM Mannitol, pH 7 5.8 3.9 96 
30 mM Phosphate, 250 mM Mannitol, pH 7 6.7 5.4 91 
30 mM Phosphate, pH 7.5 6.1 20 79 
30 mM Phosphate, 20 mM Mannitol, pH 7.5 2.4 21.3 82 
30 mM Phosphate, 100 mM Mannitol, pH 7.5 5.2 1 88 
30 mM Phosphate, 150 mM Mannitol, pH 7.5 7.0 2.1 92 
30 mM Phosphate, 250 mM Mannitol, pH 7.5 7.3 3.1 64 
88 mM Phosphate, 20 mM Mannitol, pH 7 2.1 18.4 96 
TARGET <5% <10% 100+-10 
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capsule was removed and stored separately. Capsules were washed briefly with sodium 
phosphate buffer (pH 6.0) followed by submersion in sodium phosphate buffer (pH 6.8). 
Aliquots were removed from each tube following light vortexing at 5, 10, 15, 30, 60, 90, 120, 
and 180 min and stored individually. EPT release from individual capsules was analyzed by 
CTB sandwich ELISA. 
 
CTB sandwich ELISA. The concentration of EPT standard was measured by Nanodrop 
(Thermo Fisher Scientific). Plates were coated with 100 µL per well of 2.5 µg/mL of the rat 
anti-CTB monoclonal antibody 7A12B3 diluted in PBS. After overnight incubation (16 to 
24 h) at 4ᵒC, plates were washed three times with PBST (0.05% Tween 20 in 1X PBS) and 
blocked with a blocking solution (3% bovine serum albumin, 0.05% Tween 20 in 1X PBS) 
for 2 h at room temperature, then washed with PBST in triplicate. Three-fold serially diluted, 
duplicate standard samples (100 µL/well) were added to plates in dilution buffer (1% bovine 
serum albumin, 0.05% Tween 20 in 1X PBS). Unknown samples were diluted 1:10 in 
dilution buffer and added to plates in duplicate (100 µL/well).  Samples were incubated on 
plates for 1 h at room temperature. Plates were washed and rabbit anti-CTB polyclonal 
antibody (Abcam; Cambridge, United Kingdom) diluted 1:20,000 in dilution buffer (100 
µL/well) was added; plates were then incubated at room temperature for 1 h. Plates were 
washed and goat anti-rabbit IgG-HRP (Southern Biotech; Birmingham, AL) diluted 
1:100,000 in dilution buffer was added, followed by incubation at room temperature for 1 h. 
Plates were washed a final time and developed with TMB. The reaction was stopped with 2 
N sulfuric acid and the absorbance at 450 nm was immediately measured with a BioTek plate 
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reader. Percent release was determined by extrapolation of calculated EPT concentrations 
using CTB sandwich ELISA compared to a known fixed mass of 5 µg EPT per capsule. 
 
Acute DSS colitis model and EPT treatment for capsule administration study. Groups 
of 10 female C57BL/6 mice, randomly assigned, were used. 3% DSS (M.W. 36,000 – 
50,000; M.P. Biomedicals, Santa Ana, CA) was administered in drinking water ad libitum 
for 7 days. Body weights were monitored daily from the start of DSS exposure to sacrifice 
on day 14. On the last day of DSS exposure, animals were orally gavaged 100 µL PBS,  100 
µL of EPT powder dissolved in PBS (0.03 mg/mL solution) after administration of sodium 
bicarbonate (200µL of 30 mg/mL solution) as described previously, or enteric coated 
capsules filled with 3 µg EPT (described above) [14]. Animals recovered with normal 
drinking water for 7 days. Disease activity index (DAI) scores, consisting of body weight 
loss, fecal consistency and occult blood tests, were recorded following sacrifice and 
performed as previously described [51]. Distal colon tissues were fixed in neutral buffered 
formalin and stained with hematoxalin and eosin (H&E). Histopathological scores, a 
combination score comprised of crypt architecture, inflammatory infiltrate, muscle 
thickening and goblet cell presences scores, were determined as previously described [52, 
53]. Each category was ranked on a scale from 0 to 3 and summed to obtain a single 
histopathological damage score for each tissue. 
 
Statistics. For all data, outliers were determined by statistical analysis using the Grubb’s test 
and excluded from further analysis if P < 0.05. Graphs were prepared and analyzed using 
Graphpad Prism version 5.0 (Graphpad Software, La Jolla, CA). To compare two data sets, 
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an unpaired, two-tailed Student’s t test was used. To compare three or more data sets, one-
way ANOVA with Bonferroni’s multiple-comparison post-test was used.
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CHAPTER III: RESULTS 
 
3.1. EPT at an intracolonic dose of 0.1 μM is most effective at mitigating acute 
DSS-induced colitis. 
 
 To evaluate the efficacy of EPT and determine an optimal target dose for clinical 
studies, a dose level analysis was performed using an acute DSS colitis mouse model. 
Female C57Bl/6 mice (8 weeks old) were exposed to 3% DSS ad libitum in drinking 
water for 7 days. Immediately upon DSS cessation mice were intracolonically 
administered 100 μL PBS, 0.01 μM EPT, 0.1 μM EPT, or 1 μM EPT (corresponding to 
0.0614 μg, 0.614 μg, or 6.14 μg per animal). All animals were monitored an additional 5 
days following dosing. Among the three dose levels tested, 0.1 μM EPT was the only 
dose that decreased disease activity index (DAI) scores in a statistically significant 
manner (Figure 1A). Although not statistically significant, treatment with 1 μM and 0.01 
μM EPT slightly decreased DAI scores. Histopathological assessment was performed to 
corroborate the aforementioned DAI results. Similar to the DAI results, histopathological 
damage scores indicate that 0.1 μM EPT was the most effective dose to mitigate DSS-
induced acute colitis (Figure 1B).  Interestingly, 0.01 μM EPT treatment was also 
sufficient to ameliorate histological damage compared to PBS-treated mice. Treatment 
with 1 μM EPT trended to a decreased histological damage score than the PBS group, 




Administration of 0.1 μM EPT most effectively protected mice from histological 
damage in the distal colon compared to 0.01 or 1 μM EPT (Figure 2). Treatment with 0.1 
μM EPT decreased the prevalence and incidence of crypt loss and structural alterations, 
immune cell infiltrates, and goblet cell depletion compared to 0.01 μM EPT, 1 μM EPT, 
and PBS groups. Dosing with 0.01 μM EPT protected from goblet cell depletion and 
immune cell infiltrates, however, crypt loss and structural alterations were more common 
Figure 1. Dose level analysis of intracolonic administration of EPT. Treatment with 
0.1 μM EPT is most effective at mitigating DAI and histopathological damage 
scores in acute DSS colitis. (A) DAI scores of each treatment group in the DSS 
acute colitis study. DAI is an average score consisting of body weight, stool 
consistency, and blood in stool at time of sacrifice. (B) Histopathological damage 
scores of each treatment group in the DSS acute colitis study. Histopathological 
damage score is a cumulative score consisting of crypt architecture, inflammatory 
infiltrates, muscle thickening, and goblet cell depletion from H&E-stained cross-
sections of distal colon tissue. Mean ± SD is displayed. *P < 0.05, one-way 
ANOVA with Bonferroni’s multiple comparisons test. 
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in these tissues than the 0.1 μM EPT group. Treatment with 1 μM EPT decreased 
incidences of crypt loss, immune cell infiltrates and goblet cell depletion compared to 
control, but these effects were much less pronounced than in the 0.01 and 0.1 μM EPT 
dosing groups. 
 
Figure 2. Effects of intracolonic treatment with EPT on mice colon histological 
alterations induced by DSS. Mice in the 0.1 μM dose group were more protected from 
crypt loss, inflammatory cell infiltration, and goblet cell depletion than any other group. 
Representative 5x (left) and 20x (right) photomicrographs of H&E-stained distal colon 





3.2. Pre-formulation analysis of a prototype oral formulation of EPT. 
 
Buffers and excipients were screened to determine a combination producing 
optimal EPT powder. This was determined by assessing pentamer disassembly into 
monomer, residual moisture, yield, and solubility of powder in water, with a target 
product profile (TPP) of < 5% monomer, < 10% moisture, and 100 ± 10 % solubility 
(Table 1). Of the buffers tested, PBS and PBS + 100 mM mannitol were chosen from the 
screened buffers based on the TPP values set for the aforementioned parameters. To 
assess stability of the chosen buffers, pentamer degradation and water-solubility of EPT 
formulated in PBS or PBS + 100 mM mannitol were analyzed over a period of three 
weeks (Table 2). The screened and finalized drying conditions are summarized in Table 
3. Given the importance of pentamer stability to the epithelial repair activity of EPT [30], 
Table 2.  
 
Stability of EPT powder in chosen buffer excipients. 
 
Buffer % Monomer % Solubility 
PBS 4.9 106 
PBS, 100 mM Mannitol 3.1 97 
1 Week 
PBS 5.9 110 
PBS, 100 mM Mannitol 4.0 97 
2 Weeks 
PBS 4.8 110 
PBS, 100 mM Mannitol 3.3 99 
3 Weeks 
PBS 5.9 110 
PBS, 100 mM Mannitol 3.4 99 
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PBS + 100 mM mannitol was used to optimize drying conditions and subsequent 
experiments. A variety of inlet and outlet temperature range combinations were assessed 
to determine which would result in optimal pentamer stability. A lower inlet temperature 
range (116-122 °C) and higher outlet temperature range (64-67 °C) were found to result 
in the lowest degree of pentamer degradation. Therefore, these conditions were utilized 





3.3 Stability and disintegration testing of EPT capsules. 
 
To demonstrate the stability of the chosen prototype EPT powder immediately 
after spray-drying we performed a GM1/KDEL-ELISA and SEC-HPLC to detect the 
Table 3  
 
Optimization of spray-dry parameters. 
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presence of intact KDEL sequence and the conformational state of CTB pentamer, which 
are crucial for the mucosal healing activity of EPT [11, 30]. This immunoassay and 
analytical analysis were repeated at 9 months post-spray dry with EPT powder stored 
under desiccation at 23°C in parafilm-wrapped tubes. GM1/KDEL-ELISA results 
demonstrate that GM1 binding affinity of spray dried EPT was unchanged after drying 
(Figure 3A) and 9 months post-drying when stored under desiccation at 23°C (Figure 
3B). SEC-HPLC chromatograms illustrate the stability of EPT pentamers in 9 months 
post-drying (Figure 3). The small peak of 8.2% at a retention time of ~18.5 min  
correlates to EPT monomers (see Figure S1), indicating only slight pentamer 
degradation after 9 months post-drying stored under desiccation at 23°C (Figure3D). 
Figure 3. Stability assessment of spray dried EPT. The production of EPT standard is 
described in the methods section. The stability of dried EPT post-drying and after 9 
months was assessed by GM1-capture KDEL-detection ELISA and SEC-HPLC. A 
representative binding curve of spray dried EPT is shown for (A) one day post-drying and 
(B) after 9 months stored at 23°C in a desiccator, compared to an EPT standard. SEC-
HPLC chromatogram of (C) non-dried EPT (blue) and EPT one day post-drying (green) 
and (D) dried EPT (green) after 9 months stored at 23°C in a desiccator (EPT standard is 
in blue). After 9 months dried EPT contained 91.8% pentamer and 8.2% monomer 
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Following packing of EPT powder into gelatin capsules and coating with an 
enteric coating solution, pH-dependent release of EPT was assessed by a capsule 
disintegration assay. Capsules were coated with Eudragit S100 coating solution to  
prevent the release of EPT prior to arrival at the proximal colon where the intraluminal 
pH has increased to ~pH6.8 after transiting through the stomach and small intestine [54, 
55]. The capsule disintegration assay simulated passage of the capsule through gastric 
acid and allowed us to analyze the release profile of EPT following exposure to pH 6.8.  
Recovery of EPT from capsules was determined by a CTB detection sandwich 
ELISA, which has the capacity to detect both GM1-binding pentamer and disassembled 
CTB molecular species unlike GM1-capture ELISA (Figure 4), as EPT dissociation 
Figure 4. Methodology to detect pentamer versus monomer EPT. Top left: GM1-CTB ELISA. 
STD EPT in pentamer has a much higher EC50 to GM1 than acid exposed EPT which contains 
EPT in monomer form. Top right: CTB sandwich ELISA.  STD EPT in pentamer form and 
acid exposed EPT
 
monomer form can be detected in a similar manner demonstrating capacity 
to detect both GM1-binding pentamer and disassembled CTB molecular species. Bottom: Size 
Exclusion (SEC)-HPLC.  STD EPT elutes in pentamer form at a 17.1-minute retention time 
whereas acid exposed EPT elutes in monomer form at 19.3 minutes, whereby demonstrating 
acid dissociates pentamer EPT into monomer EPT. 
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could occur if the capsule content was prematurely discharged and exposed to low pH 
conditions (Figure 4). The data revealed that EPT was released from the polymer-coated 
capsules in a pH-dependent manner (Figure 5). No EPT was detectable at pH 1.0, 
suggesting that the enteric coating prevented the release of EPT from capsules prior to 
expected release at pH 6.8. The same coating solution and method was used to prepare 
capsules used in the following acute colitis model. 
 
 
3.4. Efficacy of EPT enteric-coated capsules in an acute colitis model. 
The efficacy of EPT delivered by this oral capsule formulation was assessed compared to 
standard EPT in an acute DSS colitis mouse model [14, 30]. In this model, animals were 
exposed to 3% DSS ad libitum in drinking water for 7 days at which time mice were 
Figure 5. EPT released from enteric-coated capsules is pH-dependent. Release of EPT 
was measured by CTB sandwich ELISA. EPT releases from capsules only after 
submersion at pH 6.8. Percent of EPT release from capsules after 2 h submersion in 
0.1 N HCl, and at t=5, 10, 15, 30, 60, 90, 120, and 180 min after pH shift to 6.8. N=5. 
Percent release was determined by extrapolation of calculated EPT concentrations 




dosed 5 µg resuspended dried EPT (EPT powder solution) or PBS via oral gavage after 
administration of sodium bicarbonate. A third group of mice were dosed with an enteric-
coated capsule containing 5 µg EPT with no administration of sodium bicarbonate. All 
animals were monitored an additional 7 days following DSS cessation. Compared to 
PBS, DAI scores were decreased in mice administered a EPT capsule directly as well as 
sodium bicarbonate followed by  reconstituted EPT powder (Figure 6). To corroborate 
Figure 6. Enteric-coated EPT capsules mitigate acute DSS colitis in mice. (A) 
Study design. (B) Mice were dosed with an EPT capsule (N=10), pre-dissolved 
EPT powder following gastric acid neutralization (EPT powder solution; N=9), or 
capsule vehicle control (N=10) on day 7 following DSS exposure. DAI scores were 
determined on day 14 as a combined measure of body weight recovery, stool 
consistency, and blood in stool; data are shown as mean ± SEM. *P < 0.05, ***P < 
0.001, one-way ANOVA with Bonferroni’s multiple comparisons test. 
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the aforementioned results, we performed a histopathological evaluation to assess the 
presence of hallmark colitis markers, such as alterations in crypt height and loss, 
epithelial barrier disruption, and immune cell infiltration, in hematoxalin and eosin 
(H&E) stained tissues. EPT powder solution administration following gastric acid 
neutralization and encapsulated EPT similarly protected mice from DSS-induced acute 
colitis. Treatment with EPT by capsule administration or oral gavage following gastric 
acid neutralization protected mice from crypt loss and distortion, inflammatory cell 
infiltrates, muscle thickening, and goblet cell loss (Figure 7A, B). However, few crypt 
structural alterations, primarily crypt branching, were noted in tissues from both EPT 
Figure 7. Treatment with encapsulated EPT mitigates acute colitis in mice. 
Encapsulated EPT (DSS + Capsule) treatment protected mice from histological 
damage similarly to treatment with EPT powder solution following gastric acid 
neutralization (DSS + EPT powder solution). (A) Representative 4x (left) and 20x 
(right) photomicrographs of H&E-stained distal colon tissues from each treatment 
group. (B) Histological damage scores of each treatment group in the DSS acute 





treatment groups. Taken together, these results support equivalence between EPT 











































CHAPTER IV: DISUSSION 
 
EPT is a recombinant variant of the nontoxic component of the cholera toxin that 
exhibits unique mucosal healing activity in the colon [14, 30, 56]. Previous studies 
examining the therapeutic potential of EPT in mouse colitis models have primarily 
focused on one route of administration: oral gavage. An issue with this route of 
administration, however, is the need to neutralize gastric acid with sodium bicarbonate 
prior to gavage as CTB is acid labile. This is a drawback when moving forward with 
development of EPT as a therapeutic for UC and determining a final drug product 
formulation. Although oral agents are typically preferred by patients undergoing 
treatment for chronic diseases such as UC, gastric acid neutralization requirements could 
potentially affect patient outcomes by lowering adherence and ease of administration. 
Alternatively, we have shown that EPT also has mucosal healing activity when 
administered intracolonically. Although not necessarily the ideal formulation for a 
chronic disease, enemas are quite commonly used for the treatment of UC. Further, the 
development of an oral formulation for an acid labile protein like EPT could slow down 
efforts to begin first-in-human safety trials as more investigation and optimization is 
needed to achieve production on an industrial scale. To this end, we aimed to establish an 
intracolonic target dose for first-in-human trials as well as develop a prototype solid oral 
formulation for that would allow EPT to circumvent gastric acid degradation and allow 
for topical administration to affected areas. We described herein an encapsulated spray-
dried drug substance coated with an enteric coating to allow for pH-dependent release of 
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EPT at the colon. This oral formulation will undergo continued development and 
optimization while we move forward with a topical formulation. 
The dose level analysis study described here allowed our group to identify a target 
intracolonic dose of EPT. Establishing a target intracolonic dose of EPT is crucial to 
justify the study design of a Phase I trial. Previous studies assessing mucosal healing by 
topical delivery of EPT were primarily focused on a concentration of 1 µM, however, a 
small study hinted at the efficacy of 0.1 µM (data not shown). Therefore, we elected to 
compare the effects of 0.01, 0.1 and 1 µM (corresponding to 0.0614, 0.614, and 6.14 
µg/animal, respectively) in an acute DSS colitis model. The DAI and histological results 
indicate that 0.1 µM is the ideal target intracolonic dose of those tested. Although all 
doses of EPT led to a trending decrease in DAI scores, this difference was only 
significant in the 0.1 µM treatment group (Figure 1A). Similarly, treatment with 0.01 or 
0.1 µM EPT, but not 1 µM, significantly decreased histopathological scores (Figure 1B). 
It is currently unknown as to why EPT does not seem to induce mucosal healing in a 
dose-dependent manner, however, a possibility could lie in the ability of EPT to induce 
an unfolded protein response (UPR).  
The UPR is activated in response to ER stress to ensure protein folding fidelity 
and maintain ER functions [57]. There are three main signaling pathways of the UPR 
initiated by ER transmembrane protein sensors: IRE1α, PERK, and ATF6α. The UPR is 
commonly cited as a means for apoptosis of cells under chronic stress; however, recent 
literature has described the necessity of the UPR to intestinal homeostasis and epithelial 
barrier function [34, 35, 58, 59]. We previously demonstrated that a UPR is crucial in the 
induction of mucosal healing following treatment with EPT [30]. One possible 
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explanation for the decrease in efficacy with 1 µM EPT treatment is an overwhelming of 
the UPR leading to apoptosis. Oral gavage of 3 µg EPT alleviates DSS colitis in mice, 
which is believed to be facilitated by an EPT-induced UPR. However, a 1 µM dose of 
EPT corresponds to 6.14 µg: this is more than twice the oral gavage dose. Since the UPR 
often results in cell death upon overwhelming ER stress, it would be plausible that too 
high of a dose of EPT could trigger this pathway rather than inducing just enough of a 
response to maintain homeostasis. A limitation of this theory is the fact that a treatment 
with 1 µM EPT still slightly decreased DAI and histopathological damage scores. If this 
concentration of EPT were causing UPR-induced cell death, it would be thought that 
disease severity would be constant, or even exacerbated, compared to PBS-treated mice. 
Future studies assessing the extent of UPR upregulation following treatment with 0.01, 
0.1, and 1 µM EPT could shed some light on this interesting phenomenon. 
The most important insight gained from this dose-analysis study was the 
identification of 0.1 µM as the target intracolonic dose of EPT. Establishing a target dose 
is critical in designing future toxicology assessments and in the development of an 
Investigational New Drug (IND) application. While continuing to move forward with a 
topical formulation of EPT, we sought to begin investigation into potential oral 
formulations for future drug product development. 
A major technical advance made in the present study towards a solid oral 
formulation is the establishment of the method of drying the drug substance. Drying of 
pharmaceuticals is a long-implemented practice commonly used to enhance final drug 
product for a variety of purposes; examples of the benefits of biopharmaceutical 
dehydration include handling and storage improvement, decrease in transportation cost, 
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improved stability and aid in development of modified or delayed release particles [47, 
50]. It is known that proteins are more stable in solid rather than liquid form [60-63]. Use 
of solid formulations can greatly increase shelf-life and reduce storage regulations, saving 
patients and manufacturers money in lost production costs due to expired product. 
Further, oral capsules filled with dried protein may be coated with a time- or pH-
dependent coating to allow for targeted release in the GI tract [47]. This is especially 
useful when administering CTB orally as it allows for release at the affected site. Without 
this coating, orally administered pentameric CTB would degrade into nonfunctional 
monomers upon exposure to the stomach acid. Dehydrating CTB is one solution to this 
issue. 
Previously, CTB has been dehydrated by a variety of methods. A freeze-dried 
inactivated whole-cell oral cholera vaccine was formulated in attempts to optimize 
delivery of mass quantities of vaccine to low-income countries [7]. This formulation 
elicited strong serum and gut mucosal anti-LPS antibody responses in immunized mice; 
these responses were comparable to those achieved with equivalent liquid formulation 
[7]. The dry formulation is beneficial in substantially reducing package volumes and 
weights when delivering product to areas in need of mass vaccination. Further, CTB has 
been successfully spray-dried in the form of heat-killed Vibrio cholerae-containing 
microparticles [64]. We utilized the benefits of the spray-drying process with EPT to 
develop a more optimal oral formulation of the protein. When a protein is spray-dried, 
conditions need to be tailored to the protein being dried since materials undergo some 
thermal stress which can result in protein degradation; hence, identification of ideal 
heating conditions is critical. CTB pentamer degradation occurs approximately between 
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66 and 78°C [3, 65, 66]. Therefore, we screened outlet temperature ranges between 61 
and 67°C to maintain stability of functional EPT pentamer. Since we achieved optimal 
TPP parameters with outlet temperatures closer to 67°C, testing outlet temperatures 
closer to 78°C could possibly result in a further improved powder by solubility or 
moisture content. The most relevant source of stress during spray-drying results from the 
dehydration process, therefore the addition of excipients to the liquid solution prior to 
spray drying is crucial to replace the hydrogen bonding that exists in an aqueous 
environment [47]. In this study, a screen was developed to identify optimal excipient 
conditions to improve target profile parameters. 
A buffer and excipient screen to produce an ideal dried EPT powder based on a 
set TPP (< 5% monomer, < 10% moisture, and 100 ± 10 % solubility). Addition of a 
common excipient (mannitol) decreased the presence of EPT monomer from 
approximately 5% to 3% (Table 2, 3). It is unsurprising that addition of mannitol 
improved stability of EPT pentamer, as it is often used in dried pharmaceuticals due to its 
thermostability [67-69]. PBS + 100 mM mannitol outperformed all other screened buffers 
in the aforementioned TPP categories and was therefore chosen as the formulation buffer. 
All TPP categories were met, however, loss of drug product was a consistent problem as 
70% was the maximum recovery among all buffers tested (data not shown). Other studies 
using this particular spray drier consistently report yields below 50% [70]. Although one 
issue with this instrument is in aspects of the design, another manageable issue is 
identifying an ideal inlet to outlet temperature ratio for the protein of interest [70]. This 
limitation allows room for improvement moving forward in formulation development. 
Stability of EPT powder produced in the chosen buffer was confirmed by measuring 
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monomer content and percent solubility each week for a total of three weeks (Table 2, 3). 
Low hygroscopicity of mannitol likely had a positive impact on moisture content; it is 
known that mannitol is an ideal excipient to minimize moisture in a dried formulation 
[68, 69]. Monomer content and solubility remained stable around 3% and 98%, 
respectively, over the course of three weeks. Mannitol seems to have a protective effect 
on EPT pentamers, possibly due its thermostability. This study, however, lacked 
investigation of lactose as a potential excipient. Lactose is the most commonly utilized 
excipient in spray drying [67, 71]. Mannitol and lactose are both attractive excipients as 
they are soluble in water and are non-toxic. Lactose has an advantage to mannitol as it is 
more economical, although it should be noted that lactose has a higher hygroscopicity 
which can hinder stability of the dried product [67, 69]. Further, lactose is more likely to 
react with active pharmaceutical ingredients as it is a reducing sugar, whereas mannitol 
exhibits a strong inertness [67].  
Upon selection of buffer composition, spray dry parameters were further 
investigated. Spray dry parameters were optimized by screening a combination of inlet 
and outlet temperatures to determine a combination producing EPT powder with the best 
possible TPP values (Table 3). It has been suggested that a high inlet temperature to 
outlet temperature ratio might be the key to maximizing yield . Our results are consistent 
with this claim as the highest inlet:outlet temperature condition tested achieved optimal 
TPP values (Table 3). We also demonstrated via SEC-HPLC and GM1-KDEL detection 
ELISA that spray dried EPT maintains GM1 binding affinity and remains stable under 
dry conditions for up to 9 months (Figure 4). This combination of factors indicates that 
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EPT powder encapsulated immediately post-dry and after 9 months should exhibit similar 
effects upon administration. 
The oral formulation presented here was designed for direct delivery of EPT to 
the target site by utilizing an anionic polymer coating that makes pH-dependent release at 
the colon possible. The in vitro disintegration test suggested that not all capsules released 
100% of encased EPT (Figure 5). It is possible that there are inconsistencies in the 
thickness of the enteric coating around the capsules, leading to variations in release 
profiles. The combination of dipping capsules by and viscosity of the solution could lead 
to disparities between capsule coatings. This could be ameliorated by coating the 
capsules using an automated system that would likely be utilized when coating capsules 
at an industrial scale. Further, it was observed during disintegration testing that capsules 
tend to fold in on themselves when free-floating in solution. This is an unlikely issue in 
vivo as movement through the GI tract would prevent the folding over of capsules. In 
support of this hypothesis, the acute DSS study showed that the enteric-coated EPT 
capsule ameliorated acute DSS-induced colitis, indicating that the protein was 
successfully released from the capsules at the site of mucosal damage (Figure 6, 7). The 
histopathological results described here are also consistent with previous findings in 
acute and chronic DSS colitis studies evaluating EPT treatment [14, 30, 36]. Taken 
together, these results support further development of the capsule formulation described 
herein as this treatment does not require gastric acid neutralization, which would 





CHAPTER V: CONCLUSIONS 
 
The present studies support an established target dose of 0.1 µM for topical 
administration and continued development of a capsule formulation of EPT. More 
investigation is needed to uncover the lack of a dose-dependent response following EPT 
treatment, as this missing piece could be vital to fully elucidating its mechanism of 
action. The prototype oral formulation described here was effective at alleviating DSS-
induced acute colitis but requires further optimization, primarily of the capsule coating 
technique. Taken together, these results support continued development of EPT as a 
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